ARS Pharmaceuticals SPRY Institutional Ownership

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) showed up in the 13F filings of 208 institutional investors as of June 2026.

• Collectively, these holders controlled 91.8% of ARS Pharmaceuticals's outstanding shares in June 2026, down from 94.8% in March 2026.
• Their total shares held in SPRY increased 4.0% from the prior quarter, while the number of investors in ARS Pharmaceuticals increased 13.04% year over year.
• Of these 208 holders, 111 added to their stakes in ARS Pharmaceuticals, 57 trimmed positions, and 40 made no changes.
• Institutional investors collectively held 91.15Mn shares in ARS Pharmaceuticals as of June 2026, up by 3.51Mn shares quarter on quarter, and up 7.88Mn shares year over year.
• RA CAPITAL MANAGEMENT, L.P. holds the largest position in SPRY at 10.86Mn shares as of June 30, 2026, or 10.94% of shares outstanding.
• The most significant purchases of SPRY for the quarter ending June 2026 came from Capital World Investors (2.75Mn), Tyro Capital Management LLC (1.49Mn), BOOTHBAY FUND MANAGEMENT, LLC (1.35Mn), PEREGRINE CAPITAL MANAGEMENT LLC (672.14K), Sixth Street Partners Management Company, L.P. (551.42K).
• The largest sellers of ARS Pharmaceuticals for the quarter ending June 2026 were MILLENNIUM MANAGEMENT LLC (3.58Mn), CITADEL ADVISORS LLC (1.24Mn), ADAR1 Capital Management, LLC (760.54K), AMERICAN CENTURY COMPANIES INC (417.1K), Goldman Sachs Group Inc (343.45K).
• ARS Pharmaceuticals's 10 largest shareholders as of June 2026 include RA CAPITAL MANAGEMENT, L.P. (10.86Mn), Rubric Capital Management LP (8.54Mn), ORBIMED ADVISORS LLC (8.29Mn), DEERFIELD MANAGEMENT COMPANY, L.P. (7.5Mn), BlackRock, Inc. (5.31Mn), Tyro Capital Management LLC (4.46Mn), Aberdeen Group plc (4.17Mn), SR ONE CAPITAL MANAGEMENT, LP (4.01Mn), State Street Corp (3.73Mn), Capital World Investors (2.75Mn) per Business Quant data.